immatics appoints Peter Chambré as Chairman
immatics biotechnologies GmbH announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has been Chairman of the Company since 2004.
Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006. Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company.
Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions. From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012, Non-executive Director of BTG plc. Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies.
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
EGene Inc. Announces Its Strategic Full-Service Distribution Alliance with AH Diagnostics of Denmark
Global Bioenergies announces break-through in direct biological production of butadiene
DSM receives grant of US Department of Energy for biotechnology research
Norwood_(charity)

Schizophrenia manifests itself in the brain structure - The symptoms of schizophrenia vary greatly from person to person

ImageBiopsy Lab - Wien, Austria
Eppendorf grows faster than the market
La Jolla Institute finds previous seasonal flu infections may provide some level of H1N1 immunity

Sequential antibiotic therapy in the laboratory and in patients - Rapid switching between different antibiotics could prevent the evolution of resistance and lead to successful treatment of patients

dimes AUTOMATION GmbH - Bonn, Germany
Q Chip appoints Tim Sparey as Chief Executive Officer - Completes £2.0 Million Funding Round
